Clinical Trial

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Study acronym: NEONIPIGA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate the complete pathologic response rate (cPRR) with neoadjuvant nivolumab and ipilimumab combination in patients with MSI and/or dMMR localized oeso-gastric cancer.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-07-01; most recent amendment 2025-06-12.
Status change: Recruiting → Active, Not Recruiting 2025-03-24
Status change: Not Yet Recruiting → Recruiting 2019-09-24
Trial Details
NCT Number NCT04006262
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators: Bristol-Myers Squibb
Conditions Localized Oesogastric Adenocarcimona, MSI and or dMMR
Enrollment 32 participants
Start Date 2019-10-23
Primary Completion 2025-10 (estimated)
Study Completion 2025-10 (estimated)
Updated on ClinicalTrials.gov 2025-06-15